Clinical Lymphoma, Myeloma & Leukemia最新文献

{"title":"Antibody Response to Pneumococcal, Influenza, and COVID-19 Vaccination in Patients With Multiple Myeloma","authors":"Pranjal Singh ,&nbsp;Charanpreet Singh ,&nbsp;Kamaljeet Kamaljeet ,&nbsp;Vijayalakshmi Aravindan Arun ,&nbsp;Radha Kanta Ratho ,&nbsp;Archana Angrup ,&nbsp;Arihant Jain ,&nbsp;Sreejesh Sreedharanunni ,&nbsp;Gaurav Prakash ,&nbsp;Alka Khadwal ,&nbsp;Pankaj Malhotra","doi":"10.1016/j.clml.2025.02.006","DOIUrl":"10.1016/j.clml.2025.02.006","url":null,"abstract":"<div><h3>Introduction</h3><div>Vaccination for common pathogens implicated in causing respiratory illness in patients with Multiple Myeloma (MM) is now recommended by most experts. However, there is limited data regarding the effectiveness of vaccination in these patients.</div></div><div><h3>Methods</h3><div>We conducted a prospective study on the efficacy of pneumococcal, influenza, and COVID-19 vaccination in patients with newly diagnosed MM treated at our center between January and June 2021.</div></div><div><h3>Results</h3><div>Thirty patients completed the vaccination and were analyzed for the effectiveness of the vaccines. A significant rise in pneumococcal (2.87 U/ml vs. 0.68 U/ml; <em>P</em> &lt; .001), Influenza (0.25 IU/L vs. 0.08 IU/L; <em>P</em> &lt; 0.001) and COVID-19 (3.86 IU/L vs. 0.24 IU/L; <em>P</em> &lt; .001) antibody titres was seen in our patients. Nineteen patients (63.3%), 16 patients (53.3%), and 16 patients (53.3%) achieved seroconversion for pneumococcus, influenza, and COVID-19 postvaccination, respectively, and exhibited a 4-fold rise in antibody titer. No serious adverse events were reported after vaccination in the cohort. During the 6-month follow-up, ten patients developed respiratory tract infections- 4 with lower respiratory tract and 6 with upper respiratory tract infections. None of the patients had infections attributable to pneumococcus, influenza, or COVID-19.</div></div><div><h3>Conclusion</h3><div>Our study showed a 50% to 60% seroconversion after vaccination against 3 common respiratory pathogens in patients with newly diagnosed MM.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages 527-531"},"PeriodicalIF":2.7,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143623782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Pharmacokinetics and Efficacy of Generic Melphalan is Comparable to Innovator Formulation in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation” [Clin Lymphoma Myeloma Leuk. 20/2 (2020) 130-135.e1]","authors":"","doi":"10.1016/j.clml.2025.01.015","DOIUrl":"10.1016/j.clml.2025.01.015","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 5","pages":"Page 379"},"PeriodicalIF":2.7,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions Acute Myeloid Leukemia: Current Status and Next Questions","authors":"Vishrut Shah,&nbsp;Farhad Ravandi","doi":"10.1016/j.clml.2025.02.001","DOIUrl":"10.1016/j.clml.2025.02.001","url":null,"abstract":"<div><div>Advances in understanding leukemogenesis in acute myeloid leukemia (AML) have led to new drug approvals in the past 4 years. Ongoing preclinical research is expected to produce more targeted therapies, reducing the need for traditional chemotherapy, while also enhancing classification systems and patient prognostication. In newly diagnosed AML, the mainstay of induction still is 7+3 regimen. In unfit adults, combination of venetoclax and hypomethylating agent has emerged to be the standard of care. Introduction of FLT3 inhibitors with the 7 plus 3 regimen has improved outcomes in FLT3 mutant patients. IDH inhibitors have recently been approved for induction in medically unfit adult. Studies focusing on triplet regimen are underway. FLT3 inhibitors and IDH inhibitors have also been approved for Relapsed and Refractory AML. Menin inhibitors are another novel class of drugs which are currently being studied for both de novo as well as relapsed and refractory AML. For consolidation in fit patients, high dose cytarabine and Allogenic transplant are still the mainstay of treatment whenever feasible. FLT3 inhibitors have been studied as long term maintenance after allogenic stem cell transplantation. As potent regimens achieve high-quality remissions, the need for sensitive assays to detect measurable residual disease (MRD) and predict relapse risk will grow. MRD monitoring using flow cytometry and molecular methods have been effective with cytarabine-based treatments and will be crucial for venetoclax therapies. Eradicating MRD is a key goal for AML subsets, with research focused on targeted and immune- based therapies to eliminate MRD and understand relapse through clonal evolution. Allogeneic stem cell transplant is the most effective treatment for residual leukemia in resistant AML but is limited by toxicity and donor availability. Immune-based strategies, including antibodies and bispecific molecules, show promise in early trials, and safer cellular therapies could expand treatment options.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages 465-475"},"PeriodicalIF":2.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions: Treatment Options for Marginal Zone Lymphoma","authors":"Maria Cristina Pirosa ,&nbsp;Anastasios Stathis ,&nbsp;Davide Rossi ,&nbsp;Emanuele Zucca","doi":"10.1016/j.clml.2025.02.002","DOIUrl":"10.1016/j.clml.2025.02.002","url":null,"abstract":"<div><div>Current classifications identify 3 primary types of marginal zone lymphoma (MZL): extra nodal, splenic, and nodal MZL. MZLs typically have excellent long-term outcomes and often do not require immediate treatment. For asymptomatic patients, active surveillance (watch-and-wait) is the standard approach. However, exceptions exist. Asymptomatic patients with Helicobacter pylori-positive gastric MZL should receive antibiotic eradication therapy upon diagnosis. Similarly, asymptomatic patients infected with hepatitis C virus (HCV) should receive antiviral therapy. Surgical resection is generally not indicated. Involved-site radiotherapy (ISRT) is recommended for localized disease (20-24Gy, depending on the anatomical site). While higher doses are often needed for curative intent, very low-dose ISRT (2×2 Gy) can achieve long-term control and provide effective palliation with minimal toxicity when a definitive cure is not the goal. Symptomatic patients with advanced-stage disease may benefit from systemic rituximab-based treatment. Rituximab monotherapy is suitable for patients who cannot tolerate chemotherapy or prioritize a low-toxicity initial approach. The combination of rituximab with bendamustine or chlorambucil can result in longer response duration and progression-free survival, but not in improved overall survival, and may be preferred for severely symptomatic patients with advanced disease. More intensive doxorubicin-containing regimens, which are more toxic, should be reserved for patients with histological transformation, aggressive presentations, or bulky masses. Although data from clinical trials are limited, several new therapies have shown encouraging results, including bispecific antibodies, chimeric antigen receptor (CAR)-T cell therapy, and small molecules. Treatment choices depend on the MZL subtype, stage, age, comorbidities, and therapeutic goals.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages 476-483"},"PeriodicalIF":2.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Impact of Next-Generation Sequencing of T-Cell Lymphomas: A Single Institution Experience","authors":"Omar Elghawy ,&nbsp;Julia Wang ,&nbsp;Olivia J. Leung ,&nbsp;Nishwant Swami ,&nbsp;Veronica Carvajal ,&nbsp;Guang Yang ,&nbsp;Daniel J. Landsburg ,&nbsp;Jakub Svoboda ,&nbsp;Sunita D. Nasta ,&nbsp;Elise A. Chong ,&nbsp;Stephen J. Schuster ,&nbsp;Colin J. Thomas ,&nbsp;Jordan S. Carter ,&nbsp;Adam Bagg ,&nbsp;Stefan K. Barta","doi":"10.1016/j.clml.2025.01.017","DOIUrl":"10.1016/j.clml.2025.01.017","url":null,"abstract":"<div><h3>Background</h3><div>The understanding of T-cell lymphoma (TCL) pathobiology has grown substantially due to gene expression profiling and high-throughput next-generation sequencing (NGS). However, real-world data on mutational profiles of mature T-cell lymphomas (TCLs) are limited, and their impact on clinical decision making has not been reported.</div></div><div><h3>Methods</h3><div>A single-institution study of biopsies from patients with histopathologically confirmed T-cell lymphomas and available NGS data between January 1, 2021, to July 1, 2023, was performed. Reported variants were classified as disease-associated or pathogenic variants (DAV), or variants of unknown significance (VUS). Individual physicians were surveyed via email regarding the impact of NGS results on next steps in patient care.</div></div><div><h3>Results</h3><div>About 94% of patients (<em>n</em> = 93) had ≥ 1 variants identified; at least 1 pathogenic variant or likely pathogenic variant was identified in 71% of patients (<em>n</em> = 70). Variants were detected in 90 unique genes with 41% (37/90) having disease-associated variants (DAV). The genes with mutations most frequently resulting in disease-associated variants in this study were <em>TET2, RHOA, DNMT3A</em> and <em>TP53, IDH2,</em> and <em>PLCG1.</em> NGS results were integral to clinical management in 19% of patients per physician survey.</div></div><div><h3>Conclusion</h3><div>This work gives insight into the real-world utility of NGS regarding clinical decision making for patients with T-cell lymphoma. Given the impact of NGS on prognostication, evaluation of therapeutic options, as well as cessation of potentially unhelpful treatments, these findings support the role of NGS as an important part in the management of T-cell lymphomas.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages 505-511.e2"},"PeriodicalIF":2.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"mRNA Expression in DLBCL Patients who are CD20 Dim With an Eye Towards More Thoughtful Design of R/R Trials, Possibly Incorporating BCMA Bite Therapy","authors":"Bruce Hough ,&nbsp;Maher Albitar","doi":"10.1016/j.clml.2025.01.016","DOIUrl":"10.1016/j.clml.2025.01.016","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages 539-541"},"PeriodicalIF":2.7,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)","authors":"Efstathios Kastritis ,&nbsp;Meral Beksac ,&nbsp;Sorina Nicoleta Badelita ,&nbsp;Eirini Katodritou ,&nbsp;Jelena Bila ,&nbsp;Emmanouil Spanoudakis ,&nbsp;Guldane Cengiz Seval ,&nbsp;Zorica Cvetkovic ,&nbsp;Olivera Markovic ,&nbsp;Selami Koçak Toprak ,&nbsp;Dimitra Dalampira ,&nbsp;Daniel Coriu ,&nbsp;Zoi Bezirgiannidou ,&nbsp;Mario Pirsic ,&nbsp;Toni Valkovic ,&nbsp;Iulia Ursuleac ,&nbsp;Aleksandra Sretenovic ,&nbsp;Angeliki Sevastoudi ,&nbsp;Josip Batinic ,&nbsp;Sinziana Barbu ,&nbsp;Meletios A. Dimopoulos","doi":"10.1016/j.clml.2024.08.007","DOIUrl":"10.1016/j.clml.2024.08.007","url":null,"abstract":"<div><h3>Background</h3><div>Bortezomib, dexamethasone and cyclophosphamide (VCd) remains a popular regimen, due to its activity and low toxicity, while bortezomib, lenalidomide and dexamethasone (VRd) is widely used in US and Europe; both are combined with anti-CD38 monoclonal antibodies but VCd and VRd have not been compared directly in adequately powered prospective trials.</div></div><div><h3>Aim</h3><div>We compared the outcomes of 1216 patients treated with VCd (<em>N</em> = 690) or VRd (<em>N</em> = 526) in a real-world setting.</div></div><div><h3>Results</h3><div>Patients treated with VCd had more often severe renal dysfunction, ISS-3 disease, hypercalcemia, elevated LDH, anemia, thrombocytopenia, poor performance while VRd-treated were older and received less often autologous transplant but more frequently maintenance but the duration of induction was similar. VRd was associated with substantially higher overall response and CR/VGPR rates to induction(<em>P</em> &lt; .001) and improved PFS and OS in univariate analysis, especially among patients with standard risk disease, without renal dysfunction and in the elderly; however, in multivariate analysis there was no significant difference in either PFS or OS. In patients strictly matched 1:1 for major prognostic variables (188 in each group, total <em>N</em> = 376), the superiority of VRd in terms of responses rates and depth of response was confirmed, but without significant PFS or OS difference.</div></div><div><h3>Conclusion</h3><div>VRd is a more active induction regimen than VCd, although use of maintenance with lenalidomide may dilute the PFS or OS benefit. VCd induction remains an option in special circumstances. With the implementation of monoclonal antibodies, VCd backbone can be considered for patients without access to or who do not tolerate VRd.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 2","pages":"Pages e71-e81"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide and Earlier Initiation of Immunosuppression","authors":"Mohammad Ma'koseh ,&nbsp;Zaid Abdel Rahman ,&nbsp;Abeer Yaseen ,&nbsp;Ahmad Mesmar ,&nbsp;Husam Abu-Jazar ,&nbsp;Salwa Saadeh ,&nbsp;Duaa Mufarrej ,&nbsp;Rozan Alfar ,&nbsp;Waleed Da'na ,&nbsp;Khalid Halahleh ,&nbsp;Hasan Hashem ,&nbsp;Akram Al-Ibraheem ,&nbsp;Kamal Al-rabi ,&nbsp;Hikmat Abdel-Razeq","doi":"10.1016/j.clml.2025.01.023","DOIUrl":"10.1016/j.clml.2025.01.023","url":null,"abstract":"<div><h3>Introduction</h3><div>Peripheral blood (PB) grafts are increasingly used in haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplant cyclophosphamide (PT-Cy). The optimal timing for initiation of immunosuppression (IS) with calcineurin inhibitors (CNI) and mycophenolate mofetil (MMF) in PB haplo-HSCT is unclear. This study evaluates the outcomes of early initiation of IS prior to PT-Cy.</div></div><div><h3>Methods</h3><div>Medical records of adult patients with hematologic malignancies who received PB haplo-HSCT with PT-Cy between 2017 and 2022 were retrospectively reviewed. IS with CNI and MMF were started on day 0 and 1 postinfusion. Statistical analyses for survival outcomes were performed using the Kaplan–Meier method, and cumulative incidence (CI) models were used to account for competing risks for relapse, and nonrelapse mortality (NRM).</div></div><div><h3>Results</h3><div>A total of 51 patients were included, with a median age of 37 years (range: 19-63) and a median follow-up of 44 months (range: 37.8-53 months). Neutrophil and platelet engraftment were achieved in 98% and 96% of patients, respectively. CRS occurred in 35.3% of patients, predominantly grade I, with only 1 patient developing grade II CRS. At 3 years, overall survival (OS) and progression free survival (PFS) were 51.8% and 50.2%, respectively, and GVHD-relapse free survival (GFRS) was 43.1%. The CI of relapse and NRM at 3 years were 28.2% and 21.6%, respectively.</div></div><div><h3>Conclusion</h3><div>Early initiation of IS in PB haplo-HSCT was associated with high rates of engraftment, low rates of CRS, and favorable long-term survival outcomes. Prospective studies are needed to validate these findings and refine IS timing.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 7","pages":"Pages e513-e523.e1"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SOHO State of the Art Updates and Next Questions | Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia","authors":"Aseel Alsouqi ,&nbsp;Jennifer A. Woyach","doi":"10.1016/j.clml.2024.05.019","DOIUrl":"10.1016/j.clml.2024.05.019","url":null,"abstract":"<div><div><span><span><span>Inhibitors of Bruton's tyrosine kinase (BTK) are among the most widely used therapies for </span>chronic lymphocytic leukemia (CLL) and established a new expectation for efficacy and safety in the treatment of this disease. Currently there are 3 covalent inhibitors of BTK approved for the treatment of CLL: </span>ibrutinib, </span>acalabrutinib<span><span>, and zanubrutinib<span>. The first-in-class covalent BTK inhibitor<span><span> is ibrutinib, which as </span>monotherapy<span> has excellent efficacy in the front-line setting with a 7-year progression free survival (PFS) of 59%. Ibrutinib-based therapies have also demonstrated superiority over standard </span></span></span></span>chemoimmunotherapy<span><span><span><span> in the front-line and the relapsed/refractory setting. Acalabrutinib is a second-generation BTK inhibitor that has higher selectivity to BTK. Acalabrutinib has efficacy in both frontline and relapsed CLL and is associated with a decreased incidence of </span>atrial fibrillation<span> and hypertension when compared to ibrutinib. Like acalabrutinib, </span></span>zanubrutinib<span> was designed to be more selective for BTK than ibrutinib and to maximize BTK inhibition in tissues. Zanubrutinib has demonstrated clinical efficacy in first line and relapsed/refractory setting. These agents are indicated as monotherapy, with dosing until </span></span>disease progression<span><span> or intolerable toxicity, and are mainly differentiated by safety profile, although efficacy differences may exist as well. Combination with CD20 </span>monoclonal antibodies<span> and/or BCL2 inhibitors are alternative options for use. Here we will review efficacy and safety considerations with these agents.</span></span></span></span></div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 2","pages":"Pages 89-95"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Access among Younger Medicaid Beneficiaries with Multiple Myeloma","authors":"Mark A. Fiala ,&nbsp;Mengmeng Ji ,&nbsp;Yi-Hsuan Shih ,&nbsp;John Huber ,&nbsp;Mei Wang ,&nbsp;Kimberly J. Johnson ,&nbsp;Hamlet Gasoyan ,&nbsp;Rong Wang ,&nbsp;Graham A. Colditz ,&nbsp;Shi-Yi Wang ,&nbsp;Su-Hsin Chang","doi":"10.1016/j.clml.2024.07.017","DOIUrl":"10.1016/j.clml.2024.07.017","url":null,"abstract":"<div><h3>Purpose</h3><div>Continuous Medicaid coverage prior to a cancer diagnosis has been associated with earlier detection and better outcomes, for patients with solid tumors. In this study, we aimed to determine if this was observed among patients with multiple myeloma, a hematologic cancer where there are no routine screening tests and most are diagnosed through acute medical events.</div></div><div><h3>Materials and methods</h3><div>This is an analysis of the Merative MarketScan Multistate Medicaid Database, a claims-based dataset. In total, 1105 patients &lt; 65 years old were included in the analyses. Among them, 66% had continuous enrollment (at least 6 months enrollment prior to myeloma), and 34% had discontinuous enrollment (2-6 months enrollment prior to myeloma). Multivariable Cox regression was used to estimate the association between continuous enrollment status and receipt of myeloma treatment within 1 year of index date.</div></div><div><h3>Results</h3><div>Only 54% of all Medicaid enrollees received myeloma therapy and only 12% received stem cell transplant within the 1^st year. Those with continuous enrollment were less likely to receive any treatment (adjusted hazard ratio [aHR] 0.59; 95% confidence interval [CI] 0.59-0.70; <em>P</em> &lt; .001) and to receive stem cell transplant (aHR 0.51; 95% CI 0.32-0.81; <em>P</em> = .005).</div></div><div><h3>Conclusion</h3><div>Patients with continuous Medicaid coverage prior to diagnosis were less likely to receive myeloma therapy. Future studies should examine whether myeloma patients with continuous Medicaid enrollment have more chronic financial instability and/or higher medical needs and, thus, have higher barriers to care.</div></div>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":"25 2","pages":"Pages 109-115"},"PeriodicalIF":2.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142104988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}